Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies to treat patients with serious diseases, including cancer and metabolic disorders. Leveraging its proprietary FUSION™ System discovery platform, Biomea Fusion designs covalent inhibitors that target key disease-driving proteins. The company’s pipeline includes novel candidates aimed at addressing unmet medical needs in oncology and diabetes. By combining advanced scientific research with a commitment to improving patient outcomes, Biomea Fusion strives to deliver transformative therapies. The company partners with leading research organizations to accelerate the development of its targeted treatments, positioning itself at the forefront of precision medicine and small molecule drug discovery.
